|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 54.05 BRL | +1.62% |
|
+1.03% | -23.78% |
| 06-29 | Eli Lilly, Regeneron Among First Companies in FDA PreCheck Pilot Program | MT |
| 06-29 | Lilly, Regeneron selected for US program to review new manufacturing plants faster | RE |
Evolution of the Average Target: Regeneron Pharmaceuticals, Inc.
Evolution of the Target Price: Regeneron Pharmaceuticals, Inc.
Changes in Analyst Recommendations: Regeneron Pharmaceuticals, Inc.
| Consensus | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Objective/dr gap | ||
|---|---|---|---|---|---|---|
 | +9.18% | |||||
| +43.4% | |||||
| +21.45% | |||||
| +1.69% | |||||
| -35.37% | |||||
| -2.95% | |||||
| +46.99% | |||||
| +2.95% | |||||
| +42.03% | |||||
| Average | +14.37% | |||||
| Weighted average by Cap. | +13.76% |
Analysts' Consensus
Analyst Consensus Detail
Consensus revision (last 18 months)
Analysts covering the company
| Canaccord Genuity | |
| Bernstein | |
| Citigroup | |
| Wells Fargo Securities | |
| Jefferies & Co. | |
| Evercore ISI | |
| BMO Capital | |
| Cantor Fitzgerald | |
| JPMorgan Chase | |
| Piper Sandler | |
| Leerink Partners | |
| RBC Capital Markets | |
| Rothschild & Co Redburn | |
| Guggenheim | |
| Morgan Stanley | |
| Raymond James | |
| Barclays | |
| Goldman Sachs | |
| TD Cowen | |
| HSBC | |
| Oppenheimer | |
| Wolfe Research | |
| BofA Securities | |
| Scotiabank | |
| UBS | |
| Baird | |
| DBS Bank | |
| Truist Securities | |
| Argus | |
| Deutsche Bank Securities | |
| WestPark Capital | |
| SVB Securities LLC | |
| EF Hutton | |
| Cowen | |
| Benchmark Capital | |
| HC Wainwright | |
| SVB Leerink | |
| Credit Suisse |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- REGN Stock
- REGN34 Stock
- Consensus Regeneron Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
